Lingfu Biotech and Heze Technology Announce Strategic Partnership to Advance Brain-Computer Interface Innovation

Aug 28, 2024 20:31 CST Updated 20:31

Life Biosciences

Experimental Animal Research Service Provider

Symbionics

Brain-Computer Interface Device Developer

Symbionics 2024 Product LaunchWas held in Beijing on August 25th,重磅推出“Symbionics SymNet"and"Symbionics Automated Implant Device SymJet"Two major product series. The new products are a culmination of years of profound accumulation in brain-computer interface technology from prestigious universities such as Tsinghua, Harvard, and MIT."A breakthrough that solves the long-standing problem in academia of being unable to stably record neuronal signals over the long term, achieving for the first time the integrated design and automated precise minimally invasive implantation of flexible neural electrode products.，Greatly promoted the development of brain-computer interface field in China, as well as the research progress in cutting-edge neuroscience studies and clinical applications.

Life Biosciences Signs Contract with Symbionics

During the Press Conference，Life Biosciences Co., Ltd.("Life Biosciences" for short) andSymbionics(hereinafter referred to as "Symbionics") officially announced a strategic partnership, aiming to achieve deep collaboration between the two parties,WillSymbionics' Brain-Computer Interface TechnologyAndLife Biosciences' Professional Competence in Model AnimalsCombined,Jointly advance the innovative development of brain-machine model animals in the fields of life sciences and biomedicine.This collaboration marks the joint exploration of two companies in the field of cutting-edge technology, with the expectation of bringing breakthrough advancements to future healthcare and scientific research.

Life Biosciences Signs Contract with Symbionics

Life Biosciences is a technical service platform focused on model animals, innovative drugs, and device research and development., with abundant experimental animal resources, professional modeling technology, and model animal experiments, provides one-stop services to customers and is committed to offering high-quality model animals and related services for life science research.Symbionics has leading research and development capabilities in the field of brain-computer interface technology., whose innovative brain-computer interface products have shown great potential in various application scenarios.

This strategic cooperation will organically combine the advantages of both parties.Life Biosciences will leverage its expertise in model animals to support Symbionics in testing and validating brain-computer interface technologies for broader biomedical applications.Both parties will jointly promote the innovative application of brain-computer interface technology in multiple fields such as neuroscience, drug development, and disease model construction, deeply explore the potential applications of brain-computer interface technology, and facilitate the continuous advancement of scientific research.

Through this collaboration, Life Biosciences and Symbionics hope to inject new vitality into life science research and biopharmaceutical development, and jointly make greater contributions to the cause of human health.

About Life Biosciences

Life Biosciences Co., Ltd. (referred to as "Life Biosciences") was established in 2021. It is committed to building an internationally leading technology service platform for model animals and innovative drug device R&D, empowering life science and biopharmaceutical research.

In fields such as the central nervous system and brain science, mental and neuro-modulation, chronic metabolic diseases, oncology, and ophthalmology, the company provides nearly 200 distinctive disease models and experimental services, including spontaneous disease models, induced models, gene-edited models, and surgical models. Special focus is placed on the unique strategic value of large animal models for accelerating the clinical translation and validation of cutting-edge drugs and innovative devices.

Currently, the company has established a nationwide layout of its own high-standard medium and large-sized experimental animal resource industry chain in China. It owns multiple experimental facilities and barrier facilities for breeding SPF-level animals in the Beijing-Tianjin-Hebei region, the Yangtze River Delta, and the Greater Bay Area. The company possesses a production license for experimental animals, a usage license, AAALAC accreditation, CNAS-CL06 certification, and other comprehensive qualification certifications.

About Symbionics

Symbionics (Beijing) Technology Co., Ltd., established on April 3, 2023, is located in Haidian District, Beijing. It is dedicated to achieving seamless interaction between humans and computers through advanced integrated brain-computer interface (BCI) technology, promoting the extension and enhancement of human cognitive abilities.

Symbionics boasts a young, dynamic, and ideal-driven team. Founded by two scientists who returned from Harvard, the company brings together nearly two decades of brain-computer interface technology experience from top universities such as Tsinghua, Harvard, and MIT. Symbionics has established the world's only fully autonomous production line in China capable of manufacturing zero-rejection brain-computer interface neural electrodes. It has completed a series of product validations in rodents, canines, and non-human primates, and is collaborating with several leading neurosurgical hospitals and teams across China to advance clinical trials. These efforts provide researchers and clinical teams with innovative tools that contribute to groundbreaking progress in brain research and the design of more effective treatments for neurological disorders.

Looking ahead, Symbionics will continue to increase its investment in research and development, expand into international markets, and achieve more breakthroughs in the field of brain-computer interface technology and the fusion of artificial intelligence with bio-intelligence, promoting a healthier and more intelligent future for humanity.